regardless of positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. These insurers are often creating barriers to coverage, like high price criteria and prior authorization that limit consumer opportunity. Analysts suggest that these… Read More